Under the Spotlight Symposium
Final Results of the WIL-31 Study – A New Treatment Standard for von Willebrand Disease Patients with Severe Bleeding?
Monday, June 26, 2023
1:15pm - 2:30pm ET
Join Alok Srivastava, Nathan Connell, Robert F. Sidonio Jr, Kateryna Vilchevska, Ana Boban and Claudia Khayat for an interactive session to explore the clinical and treatment journey of three VWD patients, as they transition from on-demand treatment to prophylaxis treatment.
The symposium focuses on new data regarding the use of wilate® prophylaxis to improve the lives of people with VWD. Topics presented include the importance of prophylaxis, including current guidelines on the management of VWD and how to identify patients who may benefit from prophylactic treatment. We discuss key learnings from the WIL-31 VWD prophylaxis study and WIL-31 patient cases from across the globe.
The symposium is open to congress participants in Montréal, and will be live-streamed for participants attending virtually.
Welcome and introduction
Alok Srivastava, IN
Why is Prophylaxis Not an Important Component of Care in VWD Patients?
Nathan Connell, US
Key Learnings from the WIL-31 VWD Prophylaxis Study
Robert F. Sidonio Jr., US
PATIENT CASES FROM WIL-31 STUDY:
Teenage Boy from Ukraine, with Type 2A VWD
Kateryna Vilchevska, UA
Adult Female from Croatia, with Type 3 VWD
Ana Boban, HR
Teenage Brothers from Lebanon, Living with VWD Inhibitors
Claudia Khayat, LB
Q&A and Concluding remarks
Meet the Speakers
Chair: Alok Srivastava
Robert Sidonio Jr.
Join live on One Source
In case you cannot join us in person for the ISTH congress in Montréal, we invite you to watch our symposium live on One Source, Octapharma's online platform.
The event is for healthcare professional only.